Risedronate once weekly prevents bone loss and reduced bone turnover in women with breast cancer treated with chemotherapy.
A small 1-year randomised, double-blind, placebo-controlled trial has examined whether once-weekly oral risedronate 35mg was efficacious and safe in preventing bone loss associated with chemotherapy in breast cancer patients.
The Risedronate’s Effect on Bone Loss in Breast Cancer (ReBBeCa) study was conducted in 87 postmenopausal women with breast cancer treated with chemotherapeutic agents with or without the concomitant use of tamoxifen or aromatase inhibitors. The primary outcomes were the 12-month changes in spine and hip bone mineral density (BMD). Secondary outcomes included changes in markers of bone resorption and formation.
After 12 months, BMD increased by 1.2% at the spine and 1.3% at the hip in women on risedronate vs decreases in the placebo group of 0.9% at the spine and 0.8% at the hip
(p <0.01, difference between groups). N-telopeptide cross-linked collagen type I (bone resorption marker) decreased by 19.3%, and N-terminal propeptide of type I procollagen (bone formation marker) decreased by 26.6% in the risedronate group vs increases in the control group. The tolerability profile of risedronate was reported to be similar to that of placebo.